Immunovia AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 0.52 million compared to SEK 0.182 million a year ago. Revenue was SEK 0.598 million compared to SEK 0.202 million a year ago.

Net loss was SEK 51.66 million compared to SEK 44.11 million a year ago. Basic loss per share from continuing operations was SEK 2.28 compared to SEK 1.95 a year ago. Diluted loss per share from continuing operations was SEK 2.28 compared to SEK 1.95 a year ago.